Moderna Raised Guidance Into a Fourth Quarter That Implies a 14% to 43% Revenue Drop — and 56% of Its $390M Profit Swing Came From Cutting R&D

Every dollar of the revenue increase came from overseas volume, with the US market flat. Moderna reported $780 million of US revenue and $533 million from international markets in the third quarter. A year earlier its COVID-19 vaccine sales were $971 million, split $781 million in the US and $190 million abroad, with RSV adding $2 million and partnership revenue $43 million. The home market delivered no growth at all, and management noted that COVID contracts for a season are typically signed in the first quarter, so shipments can move between quarters.

Oncology contributed nothing to the raise, and flu has barely started. Management pointed instead to the full-year effect of the updated COVID-19 vaccine, a limited US launch for mFLUSIVA in its first season after approval on August 5, 2026, and a possible intismeran approval as 2027 drivers. Partnership revenue was $40 million of the quarter's $1,313 million, with product sales of $1,273 million. This is a COVID-volume quarter with everything else still ahead of it.

The arithmetic undercuts the headline. Lifting 2026 growth from up to 10% to 15%–25% on a $1,944 million base moves the full-year range to $2,236 million–$2,430 million. Nine months of $1,847 million leaves $389 million–$583 million for the fourth quarter, against $678 million a year earlier. The third quarter beat consensus by $428 million; the full-year raise is worth $99 million to $293 million. The raised guide therefore cuts the fourth quarter by more than the beat added, and management confirmed shipments moved between the third and fourth quarters.

The swing to profit was bought as much as it was earned. Operating income moved from a $260 million loss to a $130 million profit, a $390 million improvement. Gross profit contributed $186 million of it, a 27% cut in research and development contributed $218 million, and selling, general and administrative expense took $14 million back. So 56% of the operating improvement came from spending less on research, and the incremental revenue converted at a 63% gross margin, below the 76% earned on the quarter as a whole, because the new volume was lower-priced international tender volume.

That cut was a decision, not a timing accident. After Moderna's norovirus vaccine candidate missed statistical significance in a Phase 3 interim analysis in July 2026, the company decided against testing it in an additional cohort, and analysts read the cost discipline as deliberate. Full-year research and development guidance fell from about $2.9 billion to about $2.7 billion, with cash costs targeted at roughly $3.8 billion excluding stock compensation, depreciation and the $900 million litigation charge. Moderna traded a failed Phase 3 for a funded launch.

The cash story did not improve; it was refinanced. Cash used in operating activities was $2.72 billion over nine months, essentially unchanged from $2.80 billion a year earlier, even as revenue grew 46% to $1.85 billion. Cash and investments stood at $8.0 billion at September 30 against $8.1 billion at the end of 2025, and the year-end guide of $8.1 billion to $8.3 billion means the company ends 2026 with the same cash it started with, after a $3.0 billion convertible and $2.9 billion of operating and capital consumption. Net cash fell from $6.2 billion to $3.8 billion over the nine months.

The terms are unusually shareholder-friendly, and that has now become a live cost. The deal was priced off a $142.77 share price on August 27 and closed at $3.0 billion on September 1, with capped calls costing $329 million to push the effective strike to $392.62. With the shares at $241.46, the notes sit about 15% in the money and roughly 14.2 million shares are now dilutive, while the capped calls protect shareholders only up to $392.62. The convert did one job well: it now dilutes about 3.6% of the share count at a strike 13% below the current price.

Upstream, Moderna fills the world outside itself. Non-US supply of mRNA-1273 has been fill-finished by Samsung Biologics at its Incheon facilities under an agreement covering hundreds of millions of doses, and Canadian supply is filled and finished by Novocol Pharma in Cambridge, Ontario. Moderna is also running patent campaigns against Pfizer, Arbutus and GSK over COVID-19 and RSV vaccine manufacture and sales. None of those relationships is disclosed as material to Moderna, because the profit pool sits inside Moderna's own plants, not with its suppliers.

Downstream, the volumes move through channels that monetize them at distribution margin rather than vaccine margin. McKesson reported $111.0 billion of quarterly revenue at a 3.6% gross margin, and Cencora reported $337.4 billion for fiscal 2026 at a 4.1% gross margin. Moderna's entire US quarter was $780 million, under 1% of McKesson's revenue, and its international quarter was $533 million. The channel can carry any volume Moderna ships without capturing any of the economics, which is the platform argument in one line: the value is the platform, not the product in the pipe.

At $241.46 the shares carry a market capitalization of about $96.4 billion on trailing revenue of $2.53 billion, roughly 38 times sales, for a business whose trailing operating cash flow is negative $1.76 billion and whose guided 2026 operating loss is still about $3.0 billion to $3.2 billion once cost of sales, research and development and selling costs are taken at the company's own guidance. The guidance raise does not touch what the market is actually paying for, which is the cancer vaccine.

In the near term the question is not the third quarter but the fourth. Moderna reports the implied $389 million to $583 million in February, and on November 12 it holds an Analyst Day at its intismeran manufacturing site in Marlborough, Massachusetts, where the 2027 plan, the flu volumes, the launch cost of the cancer vaccine and whether research spending resumes its climb get laid out. Over one to three years the swing factor is whether a 42% risk reduction becomes roughly $3 billion of annual sales for Moderna on a $6 billion-plus melanoma forecast, or whether flu and a rebuilt research line absorb the cash the convertible bought. Management has already told the market the platform still needs money after the raise.